Lymphoma, Large B-Cell, Diffuse: all 1,432 studies

Page 11 of 15. Open to participants first (358), then studies with results posted, then the rest; newest registration first within each.

• Pre-phase Treatment Before R-CHOP Chemotherapy in Elderly Patients With Newly Diagnosed DLBCLCompletedNCT03465527Phase 2
• Study of Roflumilast in Combination With Standard Chemotherapy for High-risk Diffuse Large B-cell LymphomaCompletedNCT03458546Phase 1
• Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin LymphomaCompletedNCT03458260Phase 2
• Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell LymphomaCompletedNCT03450343Phase 1
• Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell LymphomaCompletedNCT03440567Phase 1
• Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell ProductTerminatedNCT03436771
• Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell MalignanciesCompletedNCT03424603Phase 1
• INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)CompletedNCT03424122Phase 1
• Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose TherapyTerminatedNCT03422523Phase 2
• Chidamide for Patients With Relapse or Refractory Diffuse Large B-Cell Lymphoma and Follicular LymphomaStatus unknownNCT03410004Phase 2
• Abbreviated 3 Cycles of Rituximab Plus CHOP(Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised LocalizedGastrointestinal CD(Cluster of Differentiation Antigen)20(+) Diffuse Large B-cell LymphomaStatus unknownNCT03399747Phase 2
• Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell LymphomaCompletedNCT03399513Phase 2
• EBV-associated Diffuse Large B Cell LymphomaCompletedNCT03378947
• Apatinib for Relapsed and Refractory Diffuse Large B Cell LymphomaCompletedNCT03376958Phase 4
• Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)Status unknownNCT03373019Phase 2
• Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell LymphomaCompletedNCT03372837Phase 3
• Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCLStatus unknownNCT03367143Phase 2
• R-CHOP14 or R-CHOP21 &Consolidation PET-Oriented Radiotherapy (RT) in DLBCL PatientsCompletedNCT03364439Phase 2
• A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin LymphomaCompletedNCT03357627Phase 1
• Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and AdolescentsWithdrawnNCT03349346Phase 1
• A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced MalignanciesCompletedNCT03329950Phase 1
• Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell LymphomaActive, not recruitingNCT03321643Phase 1
• Thalidomide Combined With R-CHOP in Newly Diagnosed，Untreated Double-expressor Diffuse Large B-Cell Lymphoma PatientsStatus unknownNCT03318835Phase 3
• Molecular Monitoring With Circulating Tumor DNA and Nivolumab MaintenanceCompletedNCT03311958Early Phase 1
• Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCLCompletedNCT03305445Phase 1
• A Study of PLX2853 in Advanced Malignancies.CompletedNCT03297424Phase 1
• Biomarker Driven Intensified ChemoImmunotherapy With Early CNS ProphylaxisActive, not recruitingNCT03293173Phase 2
• Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory LymphomasCompletedNCT03276468Phase 2
• A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell LymphomaCompletedNCT03274492Phase 3
• Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCLCompletedNCT03259529Phase 1/2
• Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell TransplantCompletedNCT03259503Phase 1
• A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6CompletedNCT03255096Phase 1
• To Decrease Fatigue With Light TherapyCompletedNCT03242902Phase 3
• Durvalumab in DLBCL After Autologous TransplantWithdrawnNCT03241017Phase 2
• BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCTStatus unknownNCT03229616Phase 2/3
• R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCLActive, not recruitingNCT03213977Phase 3
• Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma Patients-2 (GERIAD2)CompletedNCT03211702
• Chidamide With R-CHOP Regimen for DLBCL PatientsStatus unknownNCT03201471Phase 2
• Rituximab, Cyclophosphamide, Vincristine and Prednisone (R-CHOP) Plus Metformin in Diffuse Large-B-cell LymphomaCompletedNCT03200015Phase 2
• Risk Adapted Therapy in Diffuse Large B Cell LymphomaStatus unknownNCT03188198Phase 2
• Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22Status unknownNCT03185494Phase 1/2
• A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)Active, not recruitingNCT03162536Phase 1/2
• Axicabtagene Ciloleucel Expanded Access StudyApproved for marketingNCT03153462
• Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell LymphomaStatus unknownNCT03151876Phase 2
• R±CEOP90 Versus R±CEOP75 in Newly Diagnosed Young Patients With Medium/High-risk DLBCLStatus unknownNCT03151044Phase 3
• Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin LymphomaActive, not recruitingNCT03147885Phase 1/2
• Cyclophosphamide and Alemtuzumab In LymphomaTerminatedNCT03132584Phase 1
• Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2CompletedNCT03129828Phase 1/2
• 18F-FDG PET Scan and MRI Diffusion.Evaluation of the Early Therapeutic Response of Diffuse Large B-cell LymphomaActive, not recruitingNCT03121456Not applicable
• A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological MalignanciesCompletedNCT03106428Phase 1
• Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)CompletedNCT03104478
• huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic LeukemiaTerminatedNCT03103971Phase 1
• Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20CompletedNCT03097770Phase 1/2
• Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in NHL PatientsStatus unknownNCT03079947
• Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT03072771Phase 1
• Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell LymphomaActive, not recruitingNCT03064867Phase 1/2
• PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated MalignanciesStatus unknownNCT03044743Phase 1/2
• Prospective Comparison Between FDG-PET/MR and FDG-PET/CT in Classical Hodgkin Lymphoma and DLBC Non-Hodgkin LymphomaStatus unknownNCT03042247
• Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid CancersTerminatedNCT03037645Phase 1/2
• Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell LymphomasCompletedNCT03036904Phase 1
• The Study of Pegylated Liposomal Doxorubicin Contrast Epirubicin for the Treatment of Diffuse Large B-cell LymphomaStatus unknownNCT03022123Not applicable
• Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHLCompletedNCT03019666Phase 1
• R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCLStatus unknownNCT03018626Phase 3
• Thalidomide Maintenance Treatment in DLBCLStatus unknownNCT03016000Phase 3
• Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin LymphomaCompletedNCT03015896Phase 1/2
• Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid TumorsCompletedNCT03010982Phase 1
• The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of LymphomasStatus unknownNCT03000738
• HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday LifeStatus unknownNCT03000192
• Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaActive, not recruitingNCT02992522Phase 1
• Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple MyelomaCompletedNCT02992483Phase 1
• Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCLCompletedNCT02987400Phase 2
• Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisPTerminatedNCT02983097Phase 1/2
• Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's MacroglobulinemiaStatus unknownNCT02981745Phase 1/2
• A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL SubjectsCompletedNCT02976857Phase 1
• A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)TerminatedNCT02957019Phase 1/2
• RICE-ibrutinib in Relapsed DLBCLStatus unknownNCT02955628Phase 2
• Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in WaldenstromActive, not recruitingNCT02952508Phase 2
• Decitabine Plus R-CHOP in Diffuse Large B-cell LymphomaStatus unknownNCT02951728Phase 1/2
• Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT02950220Phase 1
• Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Diffuse Large B-cell LymphomaStatus unknownNCT02931201Not applicable
• 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell LymphomaStatus unknownNCT02928861Not applicable
• A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's LymphomaTerminatedNCT02914938Phase 1
• Safety and Efficacy of MAK683 in Adult Patients With Advanced MalignanciesTerminatedNCT02900651Phase 1
• PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and LymphomaStatus unknownNCT02892695Phase 1/2
• Erythropoietin for Management of Anemia Caused by ChemotherapyCompletedNCT02890602Phase 2
• Role of CX3CR1-expressing Cells in Hematologic MalignancyStatus unknownNCT02885623
• Cell-free Circulating DNA in Primary Cutaneous LymphomasCompletedNCT02883517
• A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical StudyCompletedNCT02875548Phase 1/2
• Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell LymphomaStatus unknownNCT02871869Phase 2/3
• A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma PatientsCompletedNCT02867566Phase 3
• Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and LymphomaStatus unknownNCT02851589Phase 1/2
• a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell MalignanciesStatus unknownNCT02846584Phase 2
• R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor PrognosisStatus unknownNCT02842931Phase 3
• Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL SubjectsActive, not recruitingNCT02825836Phase 1/2
• CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and LymphomaStatus unknownNCT02819583Phase 1/2
• Low-dose Radiotherapy for Diffuse Large B-cell LymphomaStatus unknownNCT02803840Phase 2
• Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins LymphomaTerminatedNCT02793583Phase 2/3
• Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and OverStatus unknownNCT02792491Phase 2
• AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell LymphomaWithdrawnNCT02780830Phase 1
• CNS Prophylaxis in Diffuse Large B-cell LymphomaStatus unknownNCT02777736Phase 3

← Lymphoma, Large B-Cell, Diffuse overview